1. Home
  2. CMPX vs RPD Comparison

CMPX vs RPD Comparison

Compare CMPX & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$6.22

Market Cap

926.7M

Sector

Health Care

ML Signal

HOLD

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

HOLD

Current Price

$10.48

Market Cap

780.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPX
RPD
Founded
2014
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
926.7M
780.5M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CMPX
RPD
Price
$6.22
$10.48
Analyst Decision
Strong Buy
Hold
Analyst Count
11
21
Target Price
$13.44
$21.65
AVG Volume (30 Days)
2.7M
1.1M
Earning Date
02-26-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.35
Revenue
N/A
$858,667,000.00
Revenue This Year
N/A
$2.62
Revenue Next Year
N/A
$1.53
P/E Ratio
N/A
$31.72
Revenue Growth
N/A
3.08
52 Week Low
$1.33
$10.20
52 Week High
$6.88
$39.39

Technical Indicators

Market Signals
Indicator
CMPX
RPD
Relative Strength Index (RSI) 56.80 23.35
Support Level $6.05 $10.20
Resistance Level $6.88 $12.21
Average True Range (ATR) 0.40 0.64
MACD -0.00 -0.16
Stochastic Oscillator 51.81 9.11

Price Performance

Historical Comparison
CMPX
RPD

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

Share on Social Networks: